India GLP-1 weight loss drug market could reach 22 billion by 2035
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
- The China, India, and Brazil market for GLP-1 weight loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, according to J.P. Morgan estimates.
- Improving affordability, generic launches, and wider access are expected to drive adoption.
- However, penetration remains low, with India facing key barriers such as cost concerns and cultural resistance to injectable treatments.
Covered by 3 outlets across the spectrum: 33% left, 67% center, 0% right.
How each side framed it
Goldman Sachs sees AI-fueled layoffs displacing nearly 10% of workers
India’s listed AI market could gain $100 billion from IPOs, says Goldman Sachs
Timeline
First to report: The Hindu BusinessLine (); 3 articles from 3 outlets so far.
Who is covering this story
- Left-leaning (1): Insider
- Center (2): The Hindu BusinessLine, Economic Times
Sources
- India’s listed AI market could gain $100 billion from IPOs, says Goldman Sachs — The Hindu BusinessLine (center) ·
- India stands to benefit from a $22 billion market — Economic Times (center) ·
- Goldman Sachs sees AI-fueled layoffs displacing nearly 10% of workers — Insider (left-leaning, AI-estimated) ·